Next Gen Diagnostics (NGD), a pioneering entity in the realm of biotechnology whose primary focus is the provision of automated whole genome sequencing and bioinformatics, announced its strategic move to Kendall Square in Cambridge, Massachusetts. This monumental relocation propels the company to the epicenter of a thriving life sciences hub, recognized across the globe for its dynamic and groundbreaking contributions. The new central location promises accelerated growth for the company, enriched collaboration with academic and industry allies, and expedited adoption of its avant-garde sequencing-based infection detection technology within hospital systems.
Dr. Paul A. Rhodes, the CEO and Founder of Next Gen Diagnostics, mirrored this optimism, remarking on Kendall Square’s reputation as a nucleus for scientific discovery and cooperation. He affirms that positioning NGD in such an innovative community restates the company’s firm commitment to revolutionizing the field of infection prevention through real-time genomic studies.
NGD extends a low-cost integrated sequencing and bioinformatics service that presents a practical and executable sequence-based transmission detection system to hospitals. By offering user-friendly and actionable reports, infection prevention teams can efficiently identify patients linked to transmission chains and plausible root causes. This allows for proactive measures to be put in place, thus curbing further transmission. By addressing over 90% of hospital transmissions that often go unnoticed, NGD empowers healthcare providers with the ability to execute early and impactful interventions.
The corporate relocation is a significant step in NGD’s growth journey as it envisages expanding its footprint across the US while strategizing commercialization in 2025. Rendering integrated high-volume turn-key sequencing and bioinformatics services, NGD has positioned itself as a frontrunner in detecting infections in hospitals and is forging collaborations across the United States, Europe, and Israel to lead the charge in deploying WGS-based regulat. Amid these significant strides, key advisory roles continue to be established within NGD, reiterating their effort to promote real-time sequencing-based detection of transmission in hospitals.